Form 4: Acrivon Therapeutics Executives Report Changes in Beneficial Ownership

Peter Blume-Jensen and Kristina Masson, executives at Acrivon Therapeutics, report changes in their beneficial ownership of company stock due to tax withholding upon vesting of restricted stock units.

Summary

• Peter Blume-Jensen, President and CEO of Acrivon Therapeutics, and Kristina Masson, EVP Business Operations, filed Form 4 documents with the SEC.
• The filings report changes in their beneficial ownership of Acrivon Therapeutics common stock on February 14, 2025.
• These changes are due to shares being withheld by the issuer to satisfy mandatory tax withholding requirements upon the vesting of restricted stock units.
• Blume-Jensen had 37,152 shares withheld at a price of $5.42, resulting in him owning 2,305,685 shares directly.
• Masson had 579 shares withheld at a price of $5.42, resulting in her owning 316,177 shares indirectly.
• Both Blume-Jensen and Masson disclaim beneficial ownership of the securities held by their spouse, except to the extent of their pecuniary interest therein.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to stock transactions for tax purposes, indicating a neutral sentiment.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are common for publicly traded companies and are used to ensure fair market practices.

Stakeholder Impact

• The filings provide transparency to shareholders regarding insider transactions.

Key Dates

Keywords

Acrivon Therapeutics, Form 4, Beneficial Ownership, SEC Filing, Blume-Jensen, Masson, Stock, Tax Withholding, Restricted Stock Units